Prof. Henk Verheul leads Translational Cancer Research and is medical oncologist at the Department of Medical Oncology of the Radboud University Medical Center in Nijmegen, The Netherlands. He is responsible for the translational research program and the Phase I clinical trial unit. Henk Verheul is principle investigator at the Radboud Insitute for Health Sciences. In addition he is Chair of the Clinical Advisory Board of The Oncode Institute, The Netherlands.
His research is focused to improve and develop novel (combination) treatment strategies for cancer (mainly colorectal cancer) with targeted agents. He is leading multiple early phase I-II clinical trials that are accompanied by side-studies in order to learn more about the activity and targets of new anticancer therapies and to develop predictive methods for treatment outcome. Techniques that are being used to develop new treatment strategies with targeted agents are pharmacokinetic and dynamic analyses as well as genomics and (phospho)proteomics. Based on preclinical evaluations, alternative scheduling and dosing of established anticancer agents are being studied to optimize treatment outcome for patients with cancer. In addition, his research is also directed to improve the quality of life for patients with cancer.
Henk Verheul received his medical degree from the Erasmus University Medical Center in Rotterdam and his PhD (cum laude) at the VU University Medical Center, Amsterdam, The Netherlands. He completed a preclinical research fellowship at the Dept. of Surgery and Vascular Biology, Children’s Hospital, Harvard University, Boston, Massachusetts, USA and a Clinical Drug Development Fellowship at the Johns Hopkins University, Baltimore, USA. Henk Verheul was a recipient of the ASCO Foundation Young Investigator’s Award in 2006. He was former head of the department of Medical Oncology at the VU University Medical Center, Amsterdam and the co-chair of the Cancer Center Amsterdam, the research institute of the Amsterdam University Medical Center, The Netherlands. He is the recipient of research grants from the Dutch Cancer Foundation (KWF) and the Dutch Scientific Research Organization (ZONmw).